Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial

2021 ◽  
Vol 8 (12) ◽  
pp. e879-e890 ◽  
Author(s):  
Jacob D Soumerai ◽  
Anthony R Mato ◽  
Ahmet Dogan ◽  
Venkatraman E Seshan ◽  
Erel Joffe ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Minimal Residual Disease ◽  
Lymphocytic Leukaemia ◽  
Residual Disease ◽  
Phase 2 ◽  
Small Lymphocytic Lymphoma ◽  
Phase 2 Trial ◽  
Minimal Residual

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial

2021 ◽  
Vol 8 (6) ◽  
pp. e422-e432
Author(s):  
Benjamin Diamond ◽  
Neha Korde ◽  
Alexander M Lesokhin ◽  
Eric L Smith ◽  
Urvi Shah ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Phase 2 ◽  
Single Centre ◽  
Phase 2 Trial ◽  
Minimal Residual

scholarly journals Absence of Minimal Residual Disease Detectable by Facs, Southern Blot or PCR in Patients with Chronic Lymphocytic Leukaemia Treated with Fludarabine

1994 ◽  
Vol 33 (6) ◽  
pp. 627-630 ◽  
Author(s):  
Deborah S. Richardson ◽  
Stephen A. Johnson ◽  
John A. Hopkins ◽  
Denise Howe ◽  
Malcolm J. Phillips
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Southern Blot ◽  
Minimal Residual Disease ◽  
Lymphocytic Leukaemia ◽  
Residual Disease ◽  
Minimal Residual
Sign in / Sign up

Export Citation Format

Share Document